GSK’s FluLaval gains expanded age indication
PHILADELPHIA — GlaxoSmithKline has received approval from the Food and Drug Administration’s Center for Biologics Evaluation and Research expanding the indication for FluLaval Quadrivalent flu vaccine to include use in children ages 6 months and older. GSK said that previously FluLaval Quadrivalent was only cleared for active immunization against influenza A subtype viruses and type
